90347-66-3

Basic information

• Product Name: METHYL 3-IODO-4-METHYLBENZOATE
• Synonyms: 3-IODO-4-METHYLBENZOIC ACID METHYL ESTER;METHYL 3-IODO-4-METHYLBENZOATE;METHYL 3-IODO-4-METH;2-Iodo-4-(methoxycarbonyl)toluene, Methyl 3-iodo-p-toluate
• CAS NO: 90347-66-3
• Molecular Formula: C₉H₉IO₂
• Molecular Weight: 276.07
• Product Categories: Aromatic Esters;Miscellaneous;Acids & Esters;Iodine Compounds;Benzenes
• Mol File: 90347-66-3.mol
• Article Data: 20

Chemical Properties

• Melting Point: 93-95
• Boiling Point: 302.9 °C at 760 mmHg
• Flash Point: 137 °C
• Appearance: /
• Density: 1.666g/cm³
• Vapor Pressure: 0.000961mmHg at 25°C
• Refractive Index: 1.5975
• Storage Temp.: 2-8°C(protect from light)
• Water Solubility: Not miscible or difficult to mix with water.
• Sensitive: Light Sensitive
• CAS DataBase Reference: METHYL 3-IODO-4-METHYLBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-IODO-4-METHYLBENZOATE(90347-66-3)
• EPA Substance Registry System: METHYL 3-IODO-4-METHYLBENZOATE(90347-66-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 90347-66-3(Hazardous Substances Data)

Usage

Description

METHYL 3-IODO-4-METHYLBENZOATE is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique structure, which includes an iodine atom attached to a methylbenzoate group, making it a valuable building block for the development of new drugs and therapeutic agents.

Uses

Used in Pharmaceutical Industry:
METHYL 3-IODO-4-METHYLBENZOATE is used as a reagent in the synthesis of [(pyrazolo[1,5-a]pyridmidinyl)ethynyl]benzamides, which are selective discoidin domain receptor 1 (DDR1) inhibitors. These inhibitors play a crucial role in the development of targeted therapies for various diseases, including cancer, by modulating the activity of DDR1, a receptor tyrosine kinase involved in cell adhesion, migration, and proliferation.
METHYL 3-IODO-4-METHYLBENZOATE is also used as a reagent in the preparation of orally bioavailable GZD824, a compound that targets the Breakpoint Cluster Region-Abelson (Bcr-Abl) kinase. This kinase is implicated in the development of chronic myeloid leukemia (CML) and other malignancies. GZD824 has the potential to overcome antitumor drug resistance, making it a promising candidate for the treatment of CML and other Abl-dependent cancers.

InChI:InChI=1/C9H9IO2/c1-6-3-4-7(5-8(6)10)9(11)12-2/h3-5H,1-2H3

Upstream product

• 67-56-1 methanol 
• 82998-57-0 3-iodo-4-toluic acid 
• 186581-53-3 diazomethane 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 229028-10-8 methyl 4-(bromomethyl)-3-iodo-benzoate 
• 272130-53-7 3-(3-hydroxy-prop-1-ynyl)-4-methyl-benzoic acid methyl ester 
• 876189-18-3 [5-(methoxycarbonyl)-2-methylphenyl]boronic acid 
• 669009-43-2 6-[(4-cyano-phenyl)-(3-methyl-3H-imidazol-4-yl)-methoxymethyl]-3'-methoxy-biphenyl-3-carboxylic acid methyl ester 
• 272130-55-9 3-(3-bromo-propyl)-4-methyl-benzoic acid methyl ester 
• 165801-58-1 3-[3-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-propyl]-4-methyl-benzoic acid methyl ester 
• 1027396-72-0 4-methyl-3-[3-(8-oxo-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-propyl]-benzoic acid methyl ester 
• 229027-90-1 2-Iodo-4-(methoxycarbonyl)benzyl acetate 
• 229028-03-9 2-Ethynyl-4-(methyloxycarbonyl)benzyl acetate 
• 229027-96-7 4-Methoxycarbonyl-2-[2-(trimethylsilyl)ethyn-1-yl]benzyl acetate 
• 1255099-13-8 methyl 3-ethynyl-4-methylbenzoate 
• 1098102-75-0 C₁₁H₁₁ClO₃ 
• 1197357-81-5 methyl 4-methyl-3-(pyridin-2-ylethynyl)benzoate 

Relevant articles and documents

Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists

The P2X7 receptor is a promising target for the treatment of various diseases due to its significant role in inflammation and immune cell signaling. This work describes the design, synthesis, and in vitro evaluation of a series of novel derivatives bearing diverse scaffolds as potent P2X7 antagonists. Our approach was based on structural modifications of reported (adamantan-1-yl)methylbenzamides able to inhibit the receptor activation. The adamantane moieties and the amide bond were replaced, and the replacements were evaluated by a ligand-based pharmacophore model. The antagonistic potency of the synthesized analogues was assessed by two-electrode voltage clamp experiments, using Xenopus laevis oocytes that express the human P2X7 receptor. SAR studies suggested that the replacement of the adamantane ring by an aryl-cyclohexyl moiety afforded the most potent antagonists against the activation of the P2X7 cation channel, with analogue 2-chloro-N-[1-(3-(nitrooxymethyl)phenyl)cyclohexyl)methyl]benzamide (56) exhibiting the best potency with an IC50 value of 0.39 μΜ.

KINASE INHIBITORS AND USES THEREOF

This invention described herein relates to compounds of general formula (I) : (I), in which variable groups are as defined herein, and to their preparation and use. Uses for the compounds and for compositions containing them include treatment of cancer and other diseases mediated by protein kinases, such as Bcr-Abl kinase, and mutants thereof, such as the T315I mutant.

3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF

The present invention relates to the field of chemical and medicine, more particularly, 3-ethynylpyrazolopyrimidine derivatives and their preparation methods and uses. The invention provides a 3-ethynylpyrazolopyrimidine derivative, and the structure is shown in formula I. The present invention also provides preparation methods and use of 3-ethynylpyrazolopyrimidine derivatives, comprising the compounds and derivatives, and their pharmaceutical compositions for the use of the treatment and prevention of tumors.